Saxenda (Liraglutide) for Weight Loss: What It Is, How It Works & How It Compares to Newer Options

Saxenda (Liraglutide) for Weight Loss: What It Is, How It Works & How It Compares to Newer Options

Saxenda was the gold standard — before Wegovy existed.

Key Takeaways

• Saxenda is liraglutide 3mg: A daily injectable GLP-1 receptor agonist approved for chronic weight management in adults with BMI ≥30 (or ≥27 with a comorbidity).
• SCALE trial result: ~8% average body weight loss vs. placebo at 56 weeks; 32% of patients lost at least 10% of body weight.
• Wegovy nearly doubles the outcome: Semaglutide 2.4mg (Wegovy) produced ~15% weight loss in STEP 1 — roughly twice Saxenda's result, once weekly vs. Saxenda's daily.
• Still prescribed for real reasons: Cost, availability, established cardiovascular data, and some patients tolerating liraglutide better all keep Saxenda in active clinical use.
• Honest bottom line: By weight loss efficacy alone, Saxenda is the weakest of the modern GLP-1 agents. If maximizing weight loss is the goal, newer options outperform it.

Here is the tension: Saxenda works — genuinely and meaningfully. Eight percent weight loss is enough to produce clinically significant improvements in blood sugar, blood pressure, and cardiovascular risk. For millions of people who used it before Wegovy existed, Saxenda changed their lives. And yet the clinical trial data is unambiguous: newer GLP-1 agents produce substantially more weight loss, less frequently dosed. Understanding why Saxenda still gets prescribed — and who it still makes sense for — requires holding both of those truths simultaneously.

What Saxenda is and how it works

Saxenda is liraglutide 3mg — the same molecule as Victoza (the diabetes formulation), dosed higher. Liraglutide is a GLP-1 receptor agonist: a fatty-acid-modified peptide that binds to the GLP-1 receptor and activates it continuously throughout the day. It was engineered with a C-16 palmitic acid chain that binds albumin in the bloodstream, extending the natural hormone's two-minute half-life to approximately 13 hours — long enough for once-daily dosing, short enough that you need to inject every day rather than once weekly.

At the GLP-1 receptor, liraglutide does what the natural hormone does, but for much longer. In the pancreas, it stimulates insulin release in proportion to blood glucose (meaning it does not cause hypoglycemia on its own). In the gut, it slows gastric emptying — food takes longer to leave the stomach, reducing post-meal glucose spikes and creating physical satiety. In the brain's hypothalamus, it activates appetite-suppressing neuronal circuits that signal fullness and reduce the drive to eat. The 3mg dose used in Saxenda is higher than the 1.8mg dose used in Victoza for diabetes — the higher dose is necessary to achieve the central appetite suppression required for meaningful weight loss.

The SCALE trial: what the data actually shows

The SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence) trials established liraglutide 3mg's efficacy for weight management. The primary SCALE Obesity and Prediabetes trial enrolled 3,731 adults with BMI ≥30 (or ≥27 with dyslipidemia or hypertension) without type 2 diabetes at baseline. After 56 weeks:

• Average weight loss: ~8.4% of body weight in the liraglutide group vs. ~2.8% with placebo — a net ~5.6% difference attributable to the drug.

• Proportion losing ≥5%: 63% of liraglutide patients vs. 27% with placebo.

• Proportion losing ≥10%: 33% of liraglutide patients vs. 10% with placebo.

• Proportion losing ≥15%: 14% of liraglutide patients vs. 3% with placebo.

The distribution matters as much as the average. Roughly one in three Saxenda patients lost 10% or more of their body weight — a threshold associated with meaningful clinical benefits in blood pressure, blood sugar, cholesterol, and sleep apnea. A substantial minority — about 14% — lost 15% or more. The drug did not produce uniform results, and the average of 8% obscures a population that did considerably better.

How it compares to Wegovy

The STEP 1 trial enrolled a comparable population and tested semaglutide 2.4mg (Wegovy) weekly for 68 weeks. Average weight loss: ~15% — nearly double Saxenda's result at comparable time frames. The proportion losing ≥10% was approximately 70% in STEP 1, versus 33% with Saxenda in SCALE. These are not close. Semaglutide produces roughly twice the weight loss of liraglutide at its respective obesity dose, administered once weekly rather than daily.

The reason for the efficacy difference is pharmacokinetic: semaglutide's half-life of ~7 days means the GLP-1 receptor is continuously and deeply activated around the clock. Liraglutide's 13-hour half-life means receptor activation peaks and troughs within each 24-hour cycle, even with daily dosing. The sustained signal is what drives the deeper appetite suppression and greater weight loss with semaglutide. This is not a criticism of liraglutide's design — it was state of the art when developed — but the data is what the data is.

How it compares to tirzepatide

Tirzepatide (Zepbound) goes further still: 22.5% average weight loss at 72 weeks (SURMOUNT-1). Tirzepatide adds GIP receptor agonism to GLP-1R activation, which provides incremental effects on fat cell biology and possibly central appetite regulation. Compared to Saxenda's 8%, tirzepatide produces nearly three times the weight loss. The comparison is largely academic from a prescribing standpoint — the two drugs are rarely interchangeable based on cost, availability, or clinical context — but it illustrates how much the efficacy ceiling of the GLP-1 class has moved since Saxenda was approved in 2014.

Why Saxenda is still prescribed

Cost is the first reason. Saxenda has been on the market longer than Wegovy or Zepbound, generic competition is closer on the horizon, and in some formulary structures it has more favorable coverage than newer agents. For patients without insurance coverage for anti-obesity medications, out-of-pocket cost differences can make Saxenda the only realistic option.

Cardiovascular safety data is the second reason. The LEADER trial enrolled 9,340 people with type 2 diabetes and high cardiovascular risk and followed them for a median of 3.8 years. Liraglutide (at the 1.8mg diabetes dose) reduced major adverse cardiovascular events (MACE) by 13% versus placebo. This was a landmark result and gave physicians nearly four years of cardiovascular outcomes data in a high-risk population. Saxenda lacks a dedicated cardiovascular outcomes trial at the 3mg obesity dose, but the LEADER data provides substantial confidence in liraglutide's cardiovascular safety profile — more long-term data than many newer agents have accumulated.

Tolerability is the third reason. GLP-1 receptor agonists share a class side effect profile — nausea, vomiting, diarrhea — but the pharmacokinetics differ. Some patients who experienced severe or prolonged nausea on semaglutide have tolerated liraglutide's shorter-duration peak-and-trough profile better, possibly because the shorter half-life means the peak plasma level is less sustained. This is anecdotal and not established in controlled trials, but clinical experience supports it as a consideration in specific patients.

The Victoza connection: same molecule, different dose

Victoza is liraglutide 1.8mg — the diabetes formulation. It carries a cardiovascular outcomes trial (LEADER) and is used in patients with type 2 diabetes who need glucose control alongside the cardiovascular benefits. For a person with both type 2 diabetes and obesity, the prescribing decision between Victoza and Saxenda essentially becomes one of dose: 1.8mg for diabetes management with moderate weight loss, 3mg if maximizing weight loss is the priority. The same titration protocol — starting at 0.6mg and increasing weekly — applies to both; patients starting Saxenda go through the same 0.6 → 1.2 → 1.8 → 2.4 → 3mg escalation over five weeks.

Side effects: daily dosing means daily exposure

Liraglutide's side effects follow a consistent pattern across the GLP-1 class. Nausea is the most common during titration — most patients experience it, and for the majority it diminishes substantially after the first few weeks at each dose level. Vomiting and diarrhea occur less frequently. The daily injection schedule means that if peak side effects track with peak plasma levels, patients experience that peak every day rather than once weekly as with semaglutide. For some patients this is manageable because each peak is lower in absolute magnitude; for others, the daily recurrence is more disruptive than a weekly injection's side effect window.

Injection site reactions are mild for most patients. The pen device is widely considered easy to use. The daily routine, however, is a genuine adherence consideration — some patients find that the once-weekly injection schedule of newer agents significantly reduces the psychological burden of treatment.

One honest limitation: liraglutide 3mg is the lowest-efficacy of the currently approved modern GLP-1 weight management agents by trial data. Average 8% weight loss is clinically meaningful — but if reducing weight as much as possible is the primary goal, semaglutide 2.4mg (15%) and tirzepatide 15mg (22.5%) both outperform it substantially. Saxenda makes the most clinical sense when cost, availability, tolerability, or the existing LEADER cardiovascular data specifically drive the choice.

Who Saxenda makes sense for now

The patient who tried semaglutide or tirzepatide first and experienced intolerable GI side effects is one candidate. The patient whose formulary covers Saxenda but not Wegovy is another. The patient with type 2 diabetes and established cardiovascular disease who has existing experience on liraglutide (Victoza) and is dose-escalating to the obesity-indication 3mg has clinical continuity arguments in its favor. And some patients simply prefer the daily routine — a smaller, predictable daily dose feels more controllable than a larger weekly one.

Who Saxenda does not make sense for: any patient where maximizing weight loss is the primary goal and both semaglutide and tirzepatide are accessible and tolerable. In that scenario, the data points clearly toward stepping up to a more efficacious agent.

Frequently Asked Questions

Is Saxenda the same as Ozempic or Wegovy?
No. Saxenda contains liraglutide; Ozempic and Wegovy contain semaglutide. They are different molecules in the same drug class. Both are GLP-1 receptor agonists, but semaglutide has a ~7-day half-life (weekly dosing) and produces approximately double the weight loss of liraglutide at obesity-approved doses.

Can you switch from Saxenda to Wegovy?
Yes, with medical guidance. Transitioning from liraglutide to semaglutide requires starting semaglutide at its lowest dose (0.25mg weekly) rather than dose-matching, because the pharmacokinetic profiles differ enough that equivalent-effect dose conversion is not straightforward. The titration schedule for semaglutide runs 16–20 weeks to reach the full 2.4mg obesity dose.

What is the correct Saxenda dose for weight loss?
The target dose is 3mg once daily subcutaneously. The dose is titrated up from 0.6mg weekly: 0.6mg for week 1, 1.2mg for week 2, 1.8mg for week 3, 2.4mg for week 4, and 3mg from week 5 onward. If side effects are not tolerable at any step, the dose escalation can be delayed for an additional week.

Does Saxenda require a prescription?
Yes. Saxenda is a prescription medication in all markets where it is approved. It is not available over the counter.

Does Saxenda have cardiovascular outcome data?
Liraglutide has the LEADER trial data showing a 13% reduction in MACE at the 1.8mg diabetes dose. Saxenda (3mg) does not have a dedicated cardiovascular outcomes trial at the obesity dose, but the LEADER data is generally considered supportive of liraglutide's cardiovascular safety across the dose range.

Will Saxenda become generic?
Liraglutide's patents have either expired or are nearing expiration in various markets. Biosimilar versions of liraglutide are in development and beginning to enter some markets. Biosimilar GLP-1 analogues could significantly reduce the cost of liraglutide-based therapy when they become broadly available — one of the longer-term reasons Saxenda may retain relevance even as newer agents dominate on efficacy.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication.